

## Press Release Archives

January 06, 2003

### Security available for trading - Arvind Remedies Ltd. w.e.f. Jan 08, 2003

The equity shares of the following company shall be listed and admitted to dealings on the Exchange w.e.f. January 8, 2003. Trading shall be in the Normal market segment (Rolling Settlement) for all investors.

Name of the Company : Arvind Remedies Limited  
ISIN Code : INE211C01029

[Top](#)

### Press reports regarding M/s. Tata Coffee Ltd.

The press had reports on January 03, 2003 that the Tatas are now planning to merge Barista Coffee Company with Tata Coffee.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of Tata Coffee Limited.

Tata Coffee Limited has vide its letter inter-alia stated, "We wish to inform you that at this juncture no such proposal has been considered by our Company."

[Top](#)

### Press reports regarding M/s. Vesuvius India Ltd.

The press had reports that Vesuvius India Limited is learnt to have hiked the prices of its refractory products.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Vesuvius India Limited has vide its letter inter-alia stated, "The Company's pricing policy is very confidential and we do not discuss the same with analysts, reporters or any outsiders. We confirm that no reporter has contacted us and we have not issued any press release in this regard. We are therefore unaware of the source of such information and would prefer not to make any comments on the same."

[Top](#)

### Press reports regarding M/s. Nicholas Piramal India Ltd.

The press had reports that:

i) Nicholas Piramal India Limited has announced recently the merger of Sumitra Pharma's bulk drug plant with it. ii) The company is in the race to pick up a strategic stake in Hyderabad-based Shantha Biotechnics. iii) The company is in talks with the \$1.2 bn American drugmaker Ivax to market the latter's asthma inhalers in India.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to

the officials of the company.

Reply is awaited from Nicholas Piramal India Limited.

[Top](#)

### **The Exchange has successfully completed its 716<sup>th</sup> Normal Settlement**

The Exchange has successfully completed its 716<sup>th</sup> Normal Settlement (Rolling T+3 following SEBI directive) since inception i.e., Settlement Number N - 2003001 on January 06, 2003. The settlement statistics are as follows:

Particulars	Values
	N - 2003001
Total traded quantity (lakhs)	1047.45
Total traded value (Rs. In Crores)	1947.85
Total value of the settlement (Securities) (Rs. In Crores)	221.15
Total value of the settlement (Funds) (Rs. In Crores)	82.66
Shortages for the settlement	0.54%
% of Delivery ( No. of shares delivered / No. of shares traded )	20.62%

[Top](#)